NCT01905735 is a Phase 2 clinical trial of Rhustoxicodendron 30 in Rheumatoid Arthritis., sponsored by Healthcare Homoeo Charitable Society.

Who is sponsoring NCT01905735?

NCT01905735 is sponsored by Healthcare Homoeo Charitable Society.

What drugs are being tested in NCT01905735?

Interventions in NCT01905735: Rhustoxicodendron 30, placebo.

What condition does NCT01905735 study?

NCT01905735 studies Rheumatoid Arthritis..

Is NCT01905735 still recruiting?

NCT01905735 is currently status unknown. Last updated 1 August 2013.

Last reviewed 2013-08-01 · How we verify

NCT01905735

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicentric,Double-blind,Placebo Controlled,Phase-2 Study to Assess the Safety and Efficacy of Homeopathic Medicine Rhus Toxicodendron 30 in the Treatment of Rheumatoid Arthritis .

Status unknown Phase 2 Last updated 1 August 2013

What this trial tests

Phase 2 trial testing Rhustoxicodendron 30 in Rheumatoid Arthritis. in 60 participants. Status unknown.

Timeline

1 August 2013

Primary endpoint
1 January 2014

1 February 2014

Quick facts

Lead sponsor	Healthcare Homoeo Charitable Society
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	1 August 2013
Primary completion	1 January 2014
Estimated completion	1 February 2014
Sites	2 locations across India

Drugs / interventions tested

Rhustoxicodendron 30 — full drug profile →
placebo

Conditions studied

Rheumatoid Arthritis. — all drugs for Rheumatoid Arthritis. →

Sponsor

Healthcare Homoeo Charitable Society

Who can join

Adults 25 to 60, any sex, with Rheumatoid Arthritis.. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of subject With American College of Rheumatology (ACR) Criteria Improvement of at Least 20%, 50%, and 70% (ACR 20/50/70 Responders).
Time frame: 6 weeks upto 24 week
number of subject with ACR criteria improvement consisting of ACR 20,ACR50,ACR70 reduction in tender and swollen joint counts and 20%,50%,70% improvement respectively in 3 of the following 5 criteria . 1. physician global assessment of disease activity's. 2. patient global assessment of disease activity's. 3. subject assessment of pain 4. subject assessment of function disability via health asses

Sponsor's own description

the purpose of the study is to assess the safety and efficacy of commonly used Homeopathic medicine Rhustoxicodendron in 30 potency in the treatment of Rheumatoid arthritis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01905735 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Healthcare Homoeo Charitable Society
Last refreshed: 1 August 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01905735.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing